DYAX Key Stats
- Ovarian Cancer Drug Half Way There Fool Jun 13
- Amgen Drug Delays Ovarian Cancer Re-Growth, Survival Benefit Unclear Jun 12
- Commit To Buy Dyax Corp At $2.50, Earn 23.1% Annualized Jun 11
- Dyax's Management Presents at 38th Annual dbAccess Health Care Conference (Trans... May 29
- Nasdaq stocks posting largest volume increases May 24
- Dyax Corp. Announces Participation in Upcoming Investor Events Business Wire May 23
- Dyax HAE Allies℠ Awards Program Launches on Second Annual Hereditary Angioedema ... May 16
- DYAX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendm... May 15
- DYAX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holder... May 15
- Dyax Corp. (DYAX) Prices $30M Direct Offering at $2.30/Share Street Insider May 13
DYAX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Dyax Corporation is up 59.11% over the last year vs S&P 500 Total Return up 25.82%, Amgen up 43.56%, and ARCA biopharma down 56.41%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for DYAX
Pro Report PDF for DYAX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download DYAX Pro Report PDF
Pro Strategies Featuring DYAX
Did Dyax Corporation make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.